In vivo activity of an azole series of CCR2 antagonists

Smethurst, Chris A.; Bevan, Nicola; Brooks, Carl; Emmons, Amanda; Gough, Peter J.; Mookherjee, Claudette; Moores, Kitty; Peace, Simon; Philp, Joanne; Piercy, Val; Watson, Steve P.; Zippoli, Mara

doi:10.1016/j.bmcl.2012.09.020

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7A) to selectively recognize compounds of individual chemotypes. For this, we assembled a larger library containing 113 AstraZeneca and related allosteric CCR2 antagonists (AZ [120][121][122][123] ), 52 UCB Pharma antagonists [119,124], 93 Johnson & Johnson antagonists (JNJ, [125][126][127]), and 79 GlaxoSmithKline antagonists (GSK [128]) from literature, as well as 50 published [129] and patented [130] BMS compounds, and 40 patented ChemoCentryx (CCX) compounds [131][132][133]. The 5t1a pocket was then challenged with recognizing active compounds of individual chemotypes against inactives (from all chemotypes) and the original set of 2950 decoys.…”

Section: Ccr2 Allosteric Pocket Conformations Are Antagonist-chemotyp...mentioning

confidence: 99%

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Dawson,

Wadman,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

By driving monocyte chemotaxis, the chemokine receptor CCR2 shapes inflammatory responses and the formation of tumor microenvironments. This makes it a promising target in inflammation and immuno-oncology. Unfortunately, despite extensive efforts, no CCR2-targeting therapeutics have yet reached the clinic. Cited reasons include the redundancy of the chemokine system, suboptimal properties of compound candidates, and poor agreement of clinical responses with preclinical murine model studies.Structure-based drug design approaches can rationalize and greatly accelerate CCR2 compound discovery and optimization. The prerequisites for such efforts include a good atomic-level understanding of the molecular determinants of action of existing antagonists.In this study, using molecular docking and artificial-intelligence-powered compound library screening, we uncover the structural principles of small molecule antagonism and selectivity towards CCR2 and its sister receptor CCR5. We show that CCR2 orthosteric inhibitors universally occupy an inactive-state-specific tunnel between receptor helices 1 and 7; we also discover an unexpected role for an extra-helical groove accessible through this tunnel, suggesting its potential as a new targetable interface for CCR2 and CCR5 modulation. We implicate a single CCR2 residue, S1012.63, as a determinant of CCR2/CCR5 and human/mouse antagonist selectivity, and corroborate its role through experimental gain-of-function mutagenesis. We systematically identify the binding determinants for various chemotypes of allosteric antagonists. We establish a critical role of induced fit in antagonist recognition, reveal strong chemotype selectivity of existing structures, and demonstrate the high predictive potential of a new deep-learning-based compound scoring function. Finally, we expand the available CCR2 structural landscape with computationally generated chemotype-specific models well-suited for structure-based antagonist design.

show abstract